Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
Total Valuation
Verve Therapeutics has a market cap or net worth of $270.83M. The enterprise value is $35.67M.
Market Cap$270.83M
Enterprise Value$35.67M
Share Statistics
Verve Therapeutics has 88.80M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding88.80M
Owened by Insiders15.35%
Owened by Instutions44.79%
Financial Efficiency
Verve Therapeutics’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -37.25%.
Return on Equity (ROE)-40.27%
Return on Assets (ROA)-30.69%
Return on Invested Capital (ROIC)-37.25%
Return on Capital Employed (ROCE)-37.83%
Revenue Per Employee$118,000
Profits Per Employee-$725,215.328
Employee Count274
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Verve Therapeutics is -2.39. Verve Therapeutics’s PEG ratio is 0.10.
PE Ratio-2.39
PS Ratio14.69
PB Ratio0.96
Price to Fair Value0.96
Price to FCF-2.94
Price to Operating Cash Flow-3.01
PEG Ratio0.10
Income Statement
In the last 12 months, Verve Therapeutics had revenue of $32.33M and earned -$198.71M in profits. Earnings per share was -$2.36.
Revenue$32.33M
Gross Profit$27.28M
Operating Income-$228.66M
Pretax Income-$198.36M
Net Income-$198.71M
EBITDA-221.91M
Earnings Per Share (EPS)-2.36
Cash Flow
In the last 12 months, operating cash flow was -$157.69M and capital expenditures -$3.74M, giving a free cash flow of -$161.43M billion.
Operating Cash Flow-$157.69M
Free Cash Flow-$161.43M
Free Cash Flow per Share-$1.82
Dividends & Yields
Verve Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-33.98%
Earnings Yield-41.83%
Stock Price Statistics
Beta3.07
52-Week Price Change-55.40%
50-Day Moving Average6.16
200-Day Moving Average5.90
Relative Strength Index (RSI)26.42
Average Volume (3m)1.63M
Important Dates
Verve Therapeutics upcoming earnings date is May 7, 2025, Before Open.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Verve Therapeutics as a current ratio of 12.65, with Debt / Equity ratio of 0.14
Current Ratio12.65
Quick Ratio12.65
Debt to Market Cap0.15
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Verve Therapeutics has paid $349.00K in taxes.
Income Tax$349.00K
Effective Tax Rate-0.18%
Enterprise Valuation
Verve Therapeutics EV to EBITDA ratio is -1.63, with an EV/FCF ratio of -2.31.
EV to Sales11.52
EV to EBITDA-1.63
EV to Free Cash Flow-2.31
EV to Operating Cash Flow-2.36
Balance Sheet
Verve Therapeutics has $524.28M in cash and marketable securities with $69.98M in debt, giving a net cash position of -$454.30M billion.
Cash & Marketable Securities$524.28M
Total Debt$69.98M
Net Cash-$454.30M
Net Cash Per Share-$5.12
Tangible Book Value Per Share$5.86
Margins
Gross margin is 100.00%, with operating margin of -707.23%, and net profit margin of -614.59%.
Gross Margin100.00%
Operating Margin-707.23%
Pretax Margin-613.51%
Net Profit Margin-614.59%
EBITDA Margin-707.23%
EBIT Margin-707.23%
Analyst Forecast
The average price target for Verve Therapeutics is $21.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.43
Price Target Upside557.36%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast174.98%
EPS Growth Forecast25.06%